BACKGROUND: Combination chemotherapy has been the mainstay of treatment for extensive stage small celI lung cancer (SCLC) over the last 30 years even though it only gives a short prolongation in median survival time. The main goal for these patients should be palliation with the aim of improving their quality of life. OBJECTIVES: To evaluate the effectiveness of chemotherapy in extensive SCLC compared with best supportive care (BSC) or placebo treatment. SEARCH STRATEGY: MEDLINE (1966 to July 2008), EMBASE (1974 to week 31, 2008), and the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2008). Experts in the field were contacted. SELECTION CRITERIA: Randomised controlled trials in which any chemotherapy treatment was compared with placebo or BSC in patients with extensive SCLC, as first or second therapy at relapse. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and assessed study quality. We resolved disagreements by discussion. Additional information was obtained from one study author. MAIN RESULTS: Two studies were included for first-line chemotherapy. A total of 65 patients were randomised to receive either placebo or ifosfamide. Ifosfamide gave an extra mean survival of 78.5 days compared with placebo. Partial tumour response was greater with the active treatment. Toxicity was only seen in the chemotherapy group.Two studies were included for second-line chemotherapy at relapse. A total of 531 patients were randomised to receive either methotrexate-doxorubicin or symptomatic treatment, or to receive oral topotecan versus BSC. The methotrexate-doxorubicin treatment gave a median survival of 63 days longer than in the symptomatic treatment group, and 21 days longer for patients allocated to receive four or eight cycles of first-line chemotherapy, respectively.Treatment with topotecan gave a median survival of 84 days longer than in the BSC group (log-rank P = 0.01). The adjusted hazard ratio for overall survival was 0.61 (95% CI, 0.43 to 0.87). Partial or complete response in the methotrexate-doxorubicin group was 22.3%. Five patients (7%, 95% CI, 2.33 to 15.67) showed a partial response with topotecan. Toxicity was worst in the chemotherapy group. Quality of life was better in the topotecan group. AUTHORS' CONCLUSIONS: Chemotherapeutic treatment prolongs survival in comparison with placebo in patients with advanced SCLC. Nevertheless, the impact of first-line chemotherapy on quality of life and in patients with poor prognosis is unknown. Well-designed, controlled trials are needed to further evaluate the risks and benefits of different chemotherapeutic schedules in patients with advanced SCLC.
BACKGROUND: Combination chemotherapy has been the mainstay of treatment for extensive stage small celI lung cancer (SCLC) over the last 30 years even though it only gives a short prolongation in median survival time. The main goal for these patients should be palliation with the aim of improving their quality of life. OBJECTIVES: To evaluate the effectiveness of chemotherapy in extensive SCLC compared with best supportive care (BSC) or placebo treatment. SEARCH STRATEGY: MEDLINE (1966 to July 2008), EMBASE (1974 to week 31, 2008), and the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2008). Experts in the field were contacted. SELECTION CRITERIA: Randomised controlled trials in which any chemotherapy treatment was compared with placebo or BSC in patients with extensive SCLC, as first or second therapy at relapse. DATA COLLECTION AND ANALYSIS: Two authors independently extracted data and assessed study quality. We resolved disagreements by discussion. Additional information was obtained from one study author. MAIN RESULTS: Two studies were included for first-line chemotherapy. A total of 65 patients were randomised to receive either placebo or ifosfamide. Ifosfamide gave an extra mean survival of 78.5 days compared with placebo. Partial tumour response was greater with the active treatment. Toxicity was only seen in the chemotherapy group.Two studies were included for second-line chemotherapy at relapse. A total of 531 patients were randomised to receive either methotrexate-doxorubicin or symptomatic treatment, or to receive oral topotecan versus BSC. The methotrexate-doxorubicin treatment gave a median survival of 63 days longer than in the symptomatic treatment group, and 21 days longer for patients allocated to receive four or eight cycles of first-line chemotherapy, respectively.Treatment with topotecan gave a median survival of 84 days longer than in the BSC group (log-rank P = 0.01). The adjusted hazard ratio for overall survival was 0.61 (95% CI, 0.43 to 0.87). Partial or complete response in the methotrexate-doxorubicin group was 22.3%. Five patients (7%, 95% CI, 2.33 to 15.67) showed a partial response with topotecan. Toxicity was worst in the chemotherapy group. Quality of life was better in the topotecan group. AUTHORS' CONCLUSIONS: Chemotherapeutic treatment prolongs survival in comparison with placebo in patients with advanced SCLC. Nevertheless, the impact of first-line chemotherapy on quality of life and in patients with poor prognosis is unknown. Well-designed, controlled trials are needed to further evaluate the risks and benefits of different chemotherapeutic schedules in patients with advanced SCLC.
Authors: Judith van Loon; Claudia Offermann; Michel Ollers; Wouter van Elmpt; Erik Vegt; Ali Rahmy; Anne-Marie C Dingemans; Philippe Lambin; Dirk De Ruysscher Journal: Radiother Oncol Date: 2011-05-14 Impact factor: 6.280
Authors: Ana López-González; Pilar Diz; Lourdes Gutierrez; Elena Almagro; Andrés García Palomo; Mariano Provencio Journal: Ann Transl Med Date: 2013-04
Authors: Clarissa Seródio Baldotto; Eduardo Henrique Cronemberger; Paulo de Biasi; Mauro Zamboni; Aureliano Sousa; Mauro Zukin; Isabelle A Small; Carlos Gil Ferreira Journal: Support Care Cancer Date: 2012-02-10 Impact factor: 3.603
Authors: Stuart C Williamson; Robert L Metcalf; Francesca Trapani; Sumitra Mohan; Jenny Antonello; Benjamin Abbott; Hui Sun Leong; Christopher P E Chester; Nicole Simms; Radoslaw Polanski; Daisuke Nonaka; Lynsey Priest; Alberto Fusi; Fredrika Carlsson; Anders Carlsson; Mary J C Hendrix; Richard E B Seftor; Elisabeth A Seftor; Dominic G Rothwell; Andrew Hughes; James Hicks; Crispin Miller; Peter Kuhn; Ged Brady; Kathryn L Simpson; Fiona H Blackhall; Caroline Dive Journal: Nat Commun Date: 2016-11-09 Impact factor: 14.919
Authors: Manjiao Ma; Mengzhao Wang; Yan Xu; Ke Hu; Huihui Liu; Longyun Li; Wei Zhong; Li Zhang; Jing Zhao; Huazhu Wang Journal: Zhongguo Fei Ai Za Zhi Date: 2014-01
Authors: C-H Lai; K-S Park; D-H Lee; A T Alberobello; M Raffeld; M Pierobon; E Pin; E F Petricoin Iii; Y Wang; G Giaccone Journal: Oncogene Date: 2013-10-28 Impact factor: 9.867